Bluejay Diagnostics provided a corporate update summarizing recent progress and its strategic plans through 2026.

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in critical care settings, today provided a corporate update highlighting recent progress and its planned strategic trajectory through 2026.

Operational and Clinical Progress

Bluejay continues to advance its Symphony™ platform, including the Company's lead product candidate for the rapid measurement of Interleukin-6 (IL-6) to support sepsis risk assessment and critical-care decision making.

The Company confirmed that its SYMON™ II clinical study is progressing as planned, with ongoing site activities and enrollment consistent with internal timelines. Data generated from this study is intended to support the Company's regulatory strategy. Due to regulatory considerations, including FDA requirements and disclosure constraints, Bluejay may be limited in its ability to release detailed clinical data prior to regulatory submission; however, the Company intends to provide appropriate updates in accordance with the analysis of primary end points with the study's statistical analysis plan.

Manufacturing and Commercial Readiness

Bluejay continues to execute its manufacturing readiness strategy, including scale-up activities designed to support both clinical and future commercial production. Key supply-chain initiatives and process validation efforts remain on track, positioning the Company for planned regulatory submission and subsequent commercialization readiness.

The Company has achieved meaningful progress in critical raw materials, antibody supply, cartridge manufacturing preparation, and external manufacturing coordination, which collectively reduce historical supply-chain risk and support long-term scalability.

Corporate and Capital Structure Update

During February 2026, the Company announced the full exercise of previously issued prefunded warrants. These exercises represented the conversion of existing instruments into common shares and did not create incremental dilution beyond the Company's previously disclosed fully diluted share structure.

Following these exercises, the Company has approximately 972,000 shares of common stock outstanding, in addition to outstanding cash-exercisable warrants with strike prices above current trading levels.

The Company expects to report $5.2 million in cash and cash equivalents and $6.0 million in stockholders' equity as of December 31, 2025, following successful completion of a $3.8 million warrant-inducement financing in April 2025 and an additional $4.5 million PIPE financing in October 2025. The Company incurred net losses of approximately $6.8 million for the fiscal year ended December 31, 2025.

2026 Strategic Priorities

Through 2026, Bluejay's primary strategic focus areas include:

Completion and execution of the SYMON™ II study and advancement toward regulatory submission

Continued manufacturing scale-up and operational readiness for commercialization

Strengthening supply-chain robustness and production capacity

Advancement of Symphony™ platform capabilities

Ongoing engagement with investors, scientific conferences, and strategic partners

Raising additional capital as part of the Company's expectation that it will need to raise at least $20 million of further capital through the end of the 2027 fiscal year, which it hopes to do in various tranches

The Company expects to provide updates through press releases, conference participation, and other investor communications as milestones are achieved or material developments occur

Management Commentary

"Bluejay continues to execute against its core clinical, operational, and regulatory priorities," said Neil Dey, Chief Executive Officer of Bluejay Diagnostics. "Our focus through 2026 remains disciplined — advancing clinical validation, preparing manufacturing for commercialization, and positioning the Symphony platform to deliver meaningful value for patients, clinicians, and shareholders."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon
COMTEX_478971655/2227/2026-05-12T01:20:52